Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Portfolio Pulse from
Novartis announced updated results from the Phase III NATALEE trial, showing that Kisqali® (ribociclib) in combination with endocrine therapy provides a durable reduction in distant recurrence for early breast cancer patients.
December 10, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Kisqali® demonstrates a 28.5% reduction in distant recurrence in early breast cancer patients, according to updated Phase III NATALEE trial results.
The updated trial results highlight the extended efficacy of Kisqali® in reducing distant recurrence in early breast cancer, which is likely to positively impact Novartis' stock price due to increased confidence in the drug's effectiveness and potential market demand.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90